Kinnate Biopharma Inc. KNTE
We take great care to ensure that the data presented and summarized in this overview for Kinnate Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KNTE
View all-
Foresite Capital Management Iv, LLC Larkspur, CA9.67MShares$013.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.01MShares$00.48% of portfolio
-
Foresite Capital Management V, LLC Larkspur, CA3.53MShares$015.38% of portfolio
-
Lynx1 Capital Management LP San Juan, PR1.98MShares$01.37% of portfolio
-
Viking Global Investors LP1.82MShares$00.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$00.0% of portfolio
-
Deltec Asset Management LLC1.04MShares$00.56% of portfolio
-
Tang Capital Management LLC San Diego, CA978KShares$00.32% of portfolio
-
Acadian Asset Management LLC Boston, MA965KShares$00.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny888KShares$00.0% of portfolio
Latest Institutional Activity in KNTE
Top Purchases
Top Sells
About KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Insider Transactions at KNTE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 03
2024
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,578
-100.0%
|
-
|
|
Apr 03
2024
|
Keith T. Flaherty |
SELL
Sale (or disposition) back to the issuer
|
Direct |
66,377
-100.0%
|
-
|
|
Apr 03
2024
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,087
-100.0%
|
-
|
|
Apr 03
2024
|
Nima Farzan CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,186
-100.0%
|
-
|
|
Apr 03
2024
|
James B. Tananbaum |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|
|
Apr 03
2024
|
Carl L Gordon Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Orbimed Advisors LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,009,729
-100.0%
|
-
|
|
Apr 03
2024
|
Foresite Capital Management Iv, LLC > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,718,311
-100.0%
|
-
|
|
Mar 01
2024
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-0.82%
|
$1,116
$2.59 P/Share
|
|
Mar 01
2024
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.98%
|
$1,116
$2.59 P/Share
|
|
Mar 01
2024
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,506
-2.3%
|
$3,012
$2.59 P/Share
|
|
Dec 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.89%
|
$1,082
$2.25 P/Share
|
|
Dec 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.18%
|
$2,918
$2.25 P/Share
|
|
Dec 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.79%
|
$1,082
$2.25 P/Share
|
|
Sep 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.78%
|
$1,082
$2.35 P/Share
|
|
Sep 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.85%
|
$1,082
$2.35 P/Share
|
|
Sep 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.13%
|
$2,918
$2.35 P/Share
|
|
Jun 01
2023
|
Neha Krishnamohan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,459
-2.09%
|
$5,836
$4.3 P/Share
|
|
Jun 01
2023
|
Mark A Meltz COO GENERAL COUNSEL SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-1.82%
|
$2,164
$4.3 P/Share
|
|
Jun 01
2023
|
Richard Thomas Williams CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
541
-0.78%
|
$2,164
$4.3 P/Share
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 43.6M shares |
|---|---|
| Payment of exercise price or tax liability | 10.2K shares |